FDA approves dasatinib for children with Philadelphia chromosome-positive chronic myeloid leukemia
- OPACC
- Nov 13, 2017
- 1 min read
The FDA expanded the indication for dasatinib to include the treatment of children with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Comentarios